Although glycemic status in type 2 diabetes is controlled by different medications, T1D management is mostly confined to insulin therapy.8,9 There are several non-insulin medications including, thiazolidinedione, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitor metformin, and sulfonylureas that have been assessed in clinical trials, however, they are not currently permitted to be used in patients with T1D.10 The gene discussed is INS; the disease is type 2 diabetes mellitus.